此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

RC48-ADC治疗HER2低表达局部晚期或转移性乳腺癌的研究

2026年9月20日 更新者:RemeGen Co., Ltd.

评估 RC48-ADC 治疗 HER2 低表达的局部晚期或转移性乳腺癌的疗效和安全性的随机、对照、多中心 III 期临床研究

This study will compare RC48-ADC to physician choice standard treatment. Participants must have HER2-low breast cancer ,previous use of anthracyclines, and have been treated with one or two systemic chemotherapy regimens following recurrence/metastasis.

研究概览

详细说明

This study is a multi-center, randomized, open, parallel control to evaluate the effectiveness and safety of Phase III clinical trials of the efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody-Monomethyl auristatin E (MMAE) conjugate for the treatment of locally advanced or metastatic breast cancer the study.The low expression of HER2 is defined as: the immunohistochemistry (IHC) confirmed by the central laboratory detects the expression of HER2 protein as IHC 2+ and the fluorescence in situ hybridization (FISH) detection has no amplification.

研究类型

介入性

注册 (估计的)

366

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Binghe Xu, M.D.
  • 电话号码:010-87788826
  • 邮箱:bhxu@hotmail.com

学习地点

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100021
        • 招聘中
        • Oncology Hospital, Chinese Academy of Medical Sciences
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 70年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Voluntarily agree to participate in the study and sign the informed consent;
  • Subjects aged 18-70 years (including 18 years and 70 years) and not reaching the 71st birthday were all considered to be ≤70 years old;
  • Expected survival ≥12 weeks;
  • Eastern Cooperative Oncology Group(ECOG) physical condition 0 or 1;
  • For female subjects of child-bearing age women agreed to study during treatment and experimental subjects within 6 months after the end of the treatment period using an approved by the medical contraception (e.g. intrauterine device, the pill or condoms), before the study drug delivery within 7 days of pregnancy blood test must be negative (sterilization surgery or age 60 or more subjects can choose no pregnancy blood test), and must be an lactation. For male subjects: should be sterilized surgically, or agree to use a medically approved contraceptive method during the study period and for 6 months after the end of the treatment period. Control subjects after the end of the treatment period according to the choice of control drugs to determine the length of contraception.
  • Able to understand the study requirements and be willing and able to follow the study and follow-up procedures.
  • Bone marrow function:

hemoglobin ≥9g/dL; absolute neutrophil count ≥1.5×109/L; white blood cell count ≥3.0×109/L platelet ≥100 ×109/L;

  • Liver function (according to the normal value of the clinical trial center) :

serum total bilirubin ≤1.5 times the upper limit of normal value (ULN); alanine aminotransferase (ALT), aspartate aminotransferase(AST) and Alkaline phosphatase(ALP) were ≤2.5 × ULN in the absence of liver metastasis, and ALT, AST and Alkaline phosphatase(ALP) were ≤5 × ULN in the presence of liver metastasis

  • Renal function (according to the normal value of the clinical trial center) :

serum creatinine ≤1.5×ULN, or calculated by Cockcroft-Gault formula, the creatinine clearance rate (CrCl) ≥60 mL/min;

  • Cardiac function:

American New York college of cardiology (NYHA) grade < 3; left ventricular ejection fraction ≥50%;

  • Breast cancer subjects diagnosed by histology and / or cytology are currently at a locally advanced or metastatic stage and cannot be radically removed;
  • The low expression of HER2 confirmed by the IHC and FISH results of the central laboratory (defined as: IHC 2+ and no amplification of FISH); the subject can provide a specimen of the primary or metastatic tumor site (paraffin wax) for HER2 detection Block, paraffin-embedded section or fresh tissue section can be used);
  • Previous use of anthracycline drugs;
  • Received 1 or 2 systemic chemotherapy treatments after relapse / metastasis. Subjects who relapsed during adjuvant chemotherapy or within 12 months after the end of adjuvant chemotherapy were considered to have failed first-line chemotherapy after relapse / metastasis.
  • Hormone receptors are negative or positive. Hormone receptor-positive subjects need to progress after receiving endocrine therapy after relapse / metastasis or relapse after less than 2 years. Patients who are not suitable for endocrine therapy can be included in this study after undergoing chemotherapy treatment (first-line or second-line);
  • The imaging evidence confirmed by the investigator that the tumor disease progressed during or after the most recent treatment is required;
  • There has been no diagnosis of HER2 positive (HER2 IHC 3+ or FISH amplification)
  • Have not used drugs targeting HER2 (including antibodies, small molecule Tyrosine kinase inhibitor(TKIs) and antibody drug conjugates).
  • According to the RECIST 1.1 standard, there is at least one measurable lesion.

Exclusion Criteria:

  • Received chemotherapy within 4 weeks before the start of study administration (treatment with nitrosourea and mitomycin C within 6 weeks, oral fluorouracil within 2 weeks), radiotherapy (palliative for bone metastases Local radiotherapy is within 2 weeks before study administration), immunotherapy; received endocrine therapy for breast cancer within 2 weeks before study administration;
  • The research drug was used within 4 weeks before the start of study administration;
  • Have undergone major surgery within 4 weeks before the start of study administration;
  • Have received a live vaccine within 4 weeks before the start of study administration or plan to receive any vaccine during the study period;
  • Serious cardiovascular and cerebrovascular events occurred within 12 months, including but not limited to unstable angina, myocardial infarction, cerebral hemorrhage, and cerebral infarction (except for asymptomatic and untreated lacunar infarction);
  • Those who are suffering from heart disease are not suitable for enrollment, including but not limited to arrhythmia and heart failure requiring medical treatment or accompanied by symptoms;
  • There are other lung diseases requiring treatment or serious, including but not limited to active pulmonary tuberculosis, interstitial lung disease, etc ;
  • Suffering from active infection requiring systemic treatment;
  • Have active autoimmune diseases (such as the use of corticosteroids or immunosuppressive drugs, etc.) that require systemic treatment within the past 2 years, allowing related alternative treatments (such as thyroxine, insulin, or the physiology of adrenal or pituitary insufficiency Corticosteroid replacement therapy);
  • The toxicity of the previous anti-tumor therapy has not been restored to the 0 to 1 level defined by CTCAE version 5.0, of which the neurotoxicity has not been restored to 0; except for hair loss, pigmentation or other researches that do not increase the risk of medication Happening;
  • Have a clear past or current history of neurological or mental disorders, including epilepsy or dementia;
  • According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subject or affect the completion of the clinical study;
  • Positive HIV test results; patients with active hepatitis B or C (HBsAg positive and hepatitis B virus(HBV) DNA titers above the upper limit of normal; Hepatitis C Virus Antibody(HCVAb) positive hepatitis C virus (HCV) RNA titers above the upper limit of normal);
  • There is a third interstitial fluid that cannot be controlled by drainage or other methods (including a large amount of pleural effusion or ascites);
  • Known hypersensitivity or delayed allergic reaction to certain components of RC48-ADC or similar drugs;
  • Subjects who are not suitable for using any of the alternative control drugs;
  • The presence of brain metastases and / or cancerous meningitis;
  • Have other malignant tumors within 5 years before signing the informed consent form (except for non-melanoma skin cancer, cervical carcinoma in situ or other tumors that have been effectively treated, except malignant tumors that are considered cured);
  • Subjects who are estimated to be inadequate for patients to participate in this clinical study or other factors that the investigator believes are inappropriate to participate in this study;

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:RC48-ADC

RC48-ADC common name:Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection Dosage form:Lyophilized powder injection specification:60 mg / piece Medication plan:Every 2 weeks Expiration date:18 months HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis.

RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks

其他名称:
  • RC48
有源比较器:Physician's Choice

Physician's Choice:

HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis.

Physician's choice from the following options:

Paclitaxel Injection Docetaxel Injection Vinorelbine Tartrate Injection Capecitabine Tablets

Administered according to label, as one option for Physician's Choice (determined before randomization)

其他名称:
  • 紫杉醇

Administered according to label, as one option for Physician's Choice (determined before randomization)

其他名称:
  • 泰索帝

Administered according to label, as one option for Physician's Choice (determined before randomization)

其他名称:
  • 脐橙

Administered according to label, as one option for Physician's Choice (determined before randomization)

其他名称:
  • 希罗达

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Progression-free survival (PFS), evaluated by an independent efficacy evaluation committee
大体时间:within approximately 3 years

Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard.

within approximately 3 years

次要结果测量

结果测量
措施说明
大体时间
Progression-free survival (PFS), evaluated by the investigator
大体时间:within approximately 3 years

Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard.

within approximately 3 years
Objective remission rate (ORR)
大体时间:within approximately 3 years

The objective response rate will be mainly analyzed by the independent efficacy evaluation committee according to the RECIST 1.1 standard tumor evaluation (the evaluation by the investigator will also be performed).

within approximately 3 years
Duration of relief (DOR)
大体时间:within approximately 3 years

DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death

within approximately 3 years
Disease control rate (DCR)
大体时间:within approximately 3 years

Disease control rate (DCR) is defined as cases where objective remission (assessed as complete remission or partial remission according to RECIST 1.1 standard) or stable disease during the study.

within approximately 3 years
Tumor progression time (TTP)
大体时间:within approximately 3 years

Time to disease progression (TTP) refers to the time from the random date to the first disease progression (calculated by the event that occurred first). Disease progression will be evaluated by the investigator according to the RECIST 1.1 standard (investigator and Independent Review Committee(IRC) evaluation).

within approximately 3 years
Overall survival (OS)
大体时间:within approximately 3 years

Overall survival (OS) refers to the time from the date of randomization to the date of death of the subject.

within approximately 3 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Yu Jiang、West China Hospital
  • 首席研究员:Binghe Xu、Oncology Hospital, Chinese Academy of Medical Sciences
  • 首席研究员:Wei Li、Jilin University First Hospital
  • 首席研究员:Xiaojia Wang、Zhejiang Cancer Hospital
  • 首席研究员:Ying Wang、Sun Yat-sen University Cancer Prevention and Control Center
  • 首席研究员:Ning Liao、Guangdong Provincial People's Hospital
  • 首席研究员:Haibo Wang、Qingdao University Hospital
  • 首席研究员:Quchang Ouyang、Hunan Cancer Hospital
  • 首席研究员:Yueyin Pan、Anhui Provincial Hospital
  • 首席研究员:Yingying Du、The First Affiliated Hospital of Anhui Medical University
  • 首席研究员:Jin Yang、The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine
  • 首席研究员:Xiuwen Wang、Qilu Hospital of Shandong University
  • 首席研究员:Huihua Xiong、Tongji Hospital
  • 首席研究员:Xinhong Wu、Hubei Cancer Hospital
  • 首席研究员:Weimin Xie、Cancer Hospital Affiliated to Guangxi Medical University
  • 首席研究员:Xin Zhou、Chongqing University Cancer Hospital
  • 首席研究员:Li Ran、Cancer Hospital of Guizhou Province
  • 首席研究员:Yu Wang、Shanxi Province Cancer Hospital
  • 首席研究员:Jinnan Gao、Bethune Hospital of Shanxi Province
  • 首席研究员:Jingfen Wang、Linyi Cancer Hospital
  • 首席研究员:Xianhe Xie、First Affiliated Hospital of Fujian Medical University
  • 首席研究员:Ru Zeng、The First Affiliated Hospital of Xiamen University
  • 首席研究员:Airong Wang、Weihai Municipal Hospital
  • 首席研究员:Zhengqiu Zhu、The Affiliated Hospital of Xuzhou Medical University
  • 首席研究员:Sanyuan Sun、Xuzhou Central Hospital
  • 首席研究员:Qingshan Li、Affiliated Hospital of Chengde Medical College
  • 首席研究员:Aimin Zang、Affiliated Hospital of Hebei University
  • 首席研究员:Liuzhong Yang、The First Affiliated Hospital of Xinxiang Medical College
  • 首席研究员:Meili Sun、Jinan Central Hospital
  • 首席研究员:Liang Li、Zibo Central Hospital
  • 首席研究员:Guohua Yu、Weifang People's Hospital
  • 首席研究员:Xujuan Wang、Neijiang Second People's Hospital
  • 首席研究员:Ying Wang、Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  • 首席研究员:Ying Cheng、Jilin Provincial Tumor Hospital
  • 首席研究员:Jifeng Feng、Jiangsu Cancer Institute & Hospital
  • 首席研究员:Tao Sun、Liaoning Cancer Hospital & Institute
  • 首席研究员:Yuee Teng、First Hospital of China Medical University
  • 首席研究员:Shu Wang、Peking University People's Hospital
  • 首席研究员:Min Yan、Henan Cancer Hospital
  • 首席研究员:Changlu Hu、Anhui Provincial Cancer Hospital
  • 首席研究员:Zhongsheng Tong、Tianjin Cancer Hospital Airport Hospital
  • 首席研究员:Lihua Song、Shandong Cancer Hospital and Institute
  • 首席研究员:Yunjiang Liu、Hebei Medical University Fourth Hospital
  • 首席研究员:Jing Cheng、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  • 首席研究员:Peng Shen、First Affiliated Hospital of Zhejiang University
  • 首席研究员:Liangming Zhang、Yantai Yuhuangding Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年9月29日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2027年12月31日

研究注册日期

首次提交

2020年4月30日

首先提交符合 QC 标准的

2020年5月19日

首次发布 (实际的)

2020年5月22日

研究记录更新

最后更新发布 (实际的)

2026年9月23日

上次提交的符合 QC 标准的更新

2026年9月20日

最后验证

2026年9月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅